Logo image of SWAV

SHOCKWAVE MEDICAL INC (SWAV) Stock Price, Quote, News and Overview

NASDAQ:SWAV - Nasdaq - US82489T1043 - Common Stock - Currency: USD

334.75  -0.08 (-0.02%)

After market: 334.8 +0.05 (+0.01%)

SWAV Quote, Performance and Key Statistics

SHOCKWAVE MEDICAL INC

NASDAQ:SWAV (5/30/2024, 8:19:22 PM)

After market: 334.8 +0.05 (+0.01%)

334.75

-0.08 (-0.02%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High334.9
52 Week Low157
Market Cap12.57B
Shares37.54M
Float37.06M
Yearly DividendN/A
Dividend YieldN/A
PE78.21
Fwd PE53.09
Earnings (Next)08-05 2024-08-05/amc
IPO03-07 2019-03-07


SWAV short term performance overview.The bars show the price performance of SWAV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

SWAV long term performance overview.The bars show the price performance of SWAV in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of SWAV is 334.75 USD. In the past month the price increased by 1.49%. In the past year, price increased by 15.77%.

SHOCKWAVE MEDICAL INC / SWAV Daily stock chart

SWAV Latest News, Press Releases and Analysis

News Image
3 months ago - Sonder Capital

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

/PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced...

News Image
7 months ago - The Motley Fool

"Rule Breaker Investing" Mailbag: Talking Stocks and Options

We also talk with Sean Milliken, managing director of The Motley Fool Foundation’s ImpactFool (IF) Fund.

News Image
8 months ago - InvestorPlace

7 Overlooked Stocks That Belong in Every Portfolio

Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks.

News Image
8 months ago - Benzinga

Why Sarepta Therapeutics Stock Is Rising Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

News Image
9 months ago - Benzinga

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.

SWAV Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.64 223.92B
ISRG INTUITIVE SURGICAL INC 79.08 206.46B
BSX BOSTON SCIENTIFIC CORP 43.87 152.60B
SYK STRYKER CORP 32.19 149.59B
MDT MEDTRONIC PLC 17.33 116.65B
BDX BECTON DICKINSON AND CO 18.42 70.30B
EW EDWARDS LIFESCIENCES CORP 26.72 42.07B
GEHC GE HEALTHCARE TECHNOLOGY 20.6 39.72B
IDXX IDEXX LABORATORIES INC 41.34 38.08B
RMD RESMED INC 27.2 35.30B
DXCM DEXCOM INC 51.45 34.16B
PHG KONINKLIJKE PHILIPS NVR- NY 20.23 25.29B

About SWAV

Company Profile

SWAV logo image Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company is headquartered in Santa Clara, California and currently employs 1,001 full-time employees. The company went IPO on 2019-03-07. The firm is focused on development and commercialization of products intended to transform the way calcified cardiovascular disease is treated. The company provides care for the treatment of calcified cardiovascular disease through its differentiated local delivery of sonic pressure waves, intravascular lithotripsy (IVL). Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD. Its Shockwave L6 IVL catheter is a six-emitter catheter for use in its IVL System in large diameter vessels for the treatment of PAD. Its Shockwave C2 IVL catheter and Shockwave C2+ IVL catheter are two-emitter catheters for use in its IVL System for the treatment of coronary artery disease (CAD).

Company Info

SHOCKWAVE MEDICAL INC

5403 Betsy Ross Dr

Santa Clara CALIFORNIA 95054 US

CEO: Douglas Godshall

Employees: 1001

Company Website: https://shockwavemedical.com/

Phone: 15102794262

SWAV FAQ

What is the stock price of SWAV?

The current stock price of SWAV is 334.75 USD.


What is the symbol for SHOCKWAVE MEDICAL INC stock?

The exchange symbol of SHOCKWAVE MEDICAL INC is SWAV and it is listed on the Nasdaq exchange.


On which exchange is SWAV stock listed?

SWAV stock is listed on the Nasdaq exchange.


Is SWAV a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SWAV, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SWAV.


Does SWAV stock pay dividends?

SWAV does not pay a dividend.


When does SWAV stock report earnings?

SWAV will report earnings on 2024-08-05, after the market close.


What is the Price/Earnings (PE) ratio of SWAV?

The PE ratio for SWAV is 78.21. This is based on the reported non-GAAP earnings per share of 4.28 and the current share price of 334.75 USD.


SWAV Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to SWAV. When comparing the yearly performance of all stocks, SWAV is one of the better performing stocks in the market, outperforming 87.72% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SWAV Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to SWAV. SWAV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SWAV Financial Highlights

Over the last trailing twelve months SWAV reported a non-GAAP Earnings per Share(EPS) of 4.28. The EPS increased by 12.34% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.76%
ROA 9.95%
ROE 21.76%
Debt/Equity 0.97
Chartmill High Growth Momentum
EPS Q2Q%39.81%
Sales Q2Q%35.85%
EPS 1Y (TTM)12.34%
Revenue 1Y (TTM)41.44%

SWAV Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 54% to SWAV. The Buy consensus is the average rating of analysts ratings from 16 analysts.

For the next year, analysts expect an EPS growth of 36.11% and a revenue growth 27.69% for SWAV


Ownership
Inst Owners10.85%
Ins Owners5.23%
Short Float %N/A
Short RatioN/A
Analysts
Analysts53.75
Price Target330.75 (-1.19%)
EPS Next Y36.11%
Revenue Next Year27.69%